Summary of evidence and Expert Committee recommendations
The Expert Committee endorsed the inclusion of linezolid on the complementary list of the EML and EMLc as a RESERVE group antibiotic.
The Reserve group includes antibiotics that should be reserved for treatment of confirmed or
suspected infections due to multidrug-resistant organisms. Reserve group antibiotics should be
considered as ‘last resort’ options. Seven selected Reserve group antibiotics are listed as individual
medicines on the WHO Model Lists as they have a favourable benefit-risk profile and proven
activity against Critical Priority” or “High Priority” pathogens as identified by the WHO priority
pathogens list, most notably carbapenem-resistant Enterobacteriaceae. These antibiotics should
be globally accessible, but their use should be tailored to highly specific patients and settings,
when alternatives are not suitable or have failed. To preserve their effectiveness these Reserve
group antibiotics should be prioritized as key targets of national and international stewardship
programmes including regular monitoring and reporting of their use.